While BRCA1- and FANCJ-deficient tumor cells are both defective in HR, only BRCA1-deficient cells were sensitive to olaparib treatment, and this difference stemmed from distinct replication fork lengthening, which reflects replication-associated ssDNA gaps [44]. This evidence concerns the gene BRCA1 and neoplasm.